Dimerix's (ASX:DXB) potential successful interim readout could allow accelerated approval of DMX-200 in Focal Segmental Glomerulosclerosis, enabling US sales to start in the second half of calendar 2026, said Euroz Hartleys in a Monday note.

The research firm noted that the company's US entry would significantly reduce its regulatory risk, as under its US licensing deal with Amicus Therapeutics, success might unlock up to AU$119 million in development milestone payments, equivalent to around AU$0.20 per share in cash.

The research firm also noted that an additional AU$709 million could be earned in commercial milestone payments, and it would also receive tiered royalties in the low-teen to low-twenties percentage range based on US net sales.

Euroz Hartleys has maintained its speculative buy recommendation with a price target of AU$1.68.